Immutep Limited enrolled over 50% of the scheduled 154 patients in the TACTI-003 trial

mmutep Limited (ASX: IMM) announced that it has registered and randomised more than 50% of the scheduled 154 patients in the TACTI-003 Phase IIb trial. The randomised, controlled multinational TACTI-003 trial is presently adding patients at over 25 centers in the United States, Australia, and Europe and is anticipated to be fully enrolled by mid-2023.

TACTI-003 assesses the company’s first-in-class soluble LAG-3 protein eftilagimod alpha, in conjunction with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® as 1st line treatment of recurrent or metastatic head and neck squamous cell carcinoma. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, an affiliate of Merck & Co., Inc., Rahway, NJ, USA.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com